Table 2 Patient characteristics of ER + /HER2-cohort after diagnosis of metastatic disease
Characteristic | All patients (113) | ESR1 mutant (34) | ESR1 WT (79) | p-values | PIK3CA mutant (36) | PIK3CA WT (77) | p-values |
|---|---|---|---|---|---|---|---|
PR metastatic | |||||||
Positive | 47 (41.6%) | 22 (64.7%) | 25 (31.6%) | 0.006 | 19 (52.8%) | 28 (36.4%) | 0.22 |
Negative | 59 (52.2%) | 12 (35.3%) | 47 (59.5%) | 17 (47.2%) | 42 (54.5%) | ||
Unknown | 7 (6.2%) | 0 (0%) | 7 (8.9%) | 0 (0%) | 7 (9.1%) | ||
Presentation of metastatic disease | |||||||
Relapsed | 86 (76.1%) | 31 (91.2%) | 55 (69.6%) | 0.016 | 29 (80.6%) | 57 (74.0%) | 0.5 |
De novo | 27 (23.9%) | 3 (8.8%) | 24 (30.4%) | 7 (19.4%) | 20 (26.0%) | ||
Site of mets | |||||||
Liver | |||||||
Yes | 74 (65.5%) | 30 (88.2%) | 44 (55.7%) | 0.001 | 26 (72.2%) | 48 (62.3%) | 0.4 |
No | 38 (33.6%) | 4 (11.8%) | 34 (43.0%) | 10 (27.8%) | 28 (36.4%) | ||
Bone | |||||||
Yes | 87 (77.0%) | 33 (97.1%) | 54 (68.4%) | < 0.001 | 32 (88.9%) | 55 (71.4%) | 0.056 |
No | 25 (22.1%) | 1 (2.9%) | 24 (30.4%) | 4 (11.1%) | 21 (27.3%) | ||
Lung | |||||||
Yes | 38 (33.6%) | 13 (38.2%) | 24 (30.4%) | 0.51 | 12 (33.3%) | 25 (32.5%) | 1.00 |
No | 75 (66.4%) | 21 (61.8%) | 54 (68.4%) | 24 (66.7%) | 51 (66.2%) | ||
Visceral disease | |||||||
Yes | 69 (61.1%) | 25 (73.5%) | 44 (55.7%) | 0.2 | 26 (72.2%) | 43 (55.8%) | 0.21 |
No | 40 (35.4%) | 9 (26.5%) | 31 (39.2%) | 10 (27.8%) | 30 (39.0%) | ||
Unknown | 4 (3.5%) | 0 (0%) | 4 (5.1%) | 0 (0%) | 4 (5.2%) | ||
Status of metastatic disease | |||||||
New diagnosis of mets | 35 (31.0%) | 3 (8.8%) | 32 (40.5%) | < 0.001 | 9 (25.0%) | 26 (33.8%) | 0.002 |
Stable disease | 14 (12.4%) | 1 (2.9%) | 13 (16.5%) | 0 (0%) | 14(18.2%) | ||
Progressive disease | 63 (55.8%) | 30 (88.2%) | 33 (41.8%) | 27 (75.0%) | 36 (46.8%) | ||
Unknown | 1 (0.9%) | 0 (0%) | 1 (1.3%) | 0 | 1 | ||
